Tetanus Toxoid Vaccine Market Size & Growth Analysis to 2030

The global tetanus toxoid vaccines market size is anticipated to register a significant CAGR of 4.7% during the forecast period and estimated to reach USD 6,601 million by 2027. The rising prevalence of Clostridium tetani infection in the developing regions primarily drives the tetanus toxoid vaccines market growth. Furthermore, recent advancement in the technology transfer process regarding the development of polyvalent vaccines provide positive impetus to the market growth.

Tetanus is an infectious disease which is caused by the bacterium Clostridium tetani, which affects the central nervous system resulting in lockjaw and muscle stiffness, difficulty in breathing and eventually causes death if not treated early. As per the latest research citings provided by the World Health Organization (WHO), in 2017 approximately 38,000 people worldwide died due to the tetanus infection. Further in depth analysis provide vital information regarding the clinical manifestation of tetanus infection which are headache, seizures, sweating, fever, muscle spams etc.

Market Drivers:

Increasing Awareness of Tetanus Prevention: The growing awareness of the importance of tetanus prevention has played a crucial role in driving the demand for tetanus toxoid vaccines. Tetanus is a life-threatening bacterial infection that can be prevented through vaccination. Increased awareness campaigns, educational initiatives, and immunization programs have contributed to the demand for tetanus toxoid vaccines.

Government Initiatives and Immunization Programs: Governments across the world have implemented immunization programs and initiatives to prevent and control infectious diseases, including tetanus. These programs aim to vaccinate individuals, particularly infants, children, and pregnant women, against tetanus. Government support, funding, and regulatory measures have facilitated the availability and accessibility of tetanus toxoid vaccines, driving market growth.

Expanded Immunization Programs in Developing Countries: In many developing countries, there has been an expansion of immunization programs to reach underserved populations and improve healthcare infrastructure. Tetanus toxoid vaccines are included in routine immunization schedules, and efforts to increase vaccination coverage in these regions have contributed to the growth of the market.

Rising Incidence of Tetanus: Despite the availability of vaccines, tetanus cases still occur, particularly in regions with limited access to healthcare and low vaccination rates. The rising incidence of tetanus in certain areas has driven the demand for tetanus toxoid vaccines to prevent and control the disease.

Growth in Population and Birth Rates: The global population growth, coupled with increasing birth rates in many regions, has led to a higher demand for tetanus toxoid vaccines. Vaccination of pregnant women is critical to protecting newborns against tetanus, as they are at a higher risk of contracting the infection. The growth in population and birth rates has positively impacted the market.

Technological Advancements in Vaccine Production: Technological advancements in vaccine production and manufacturing processes have improved the quality, efficiency, and scalability of tetanus toxoid vaccines. These advancements have led to increased production capacities, reduced costs, and improved vaccine stability, contributing to market growth.

Collaboration between Government and Non-Governmental Organizations: Collaboration between government agencies and non-governmental organizations (NGOs) has played a significant role in expanding immunization programs and increasing vaccination coverage. These partnerships work towards improving healthcare infrastructure, raising awareness, and ensuring the availability of tetanus toxoid vaccines, driving market growth.

Market Outlook:

Market Insights:

Polyvalent vaccines are representing the largest market share in the types segment for tetanus toxoid vaccines market. Frequent skin laceration by rusted utensils, tools and repeated exposure to contaminated surface such as soil, animal and human feces etc. causes the transmission of the Clostridium tetani bacteria in human beings. It is available in different combination such as diphtheria, tetanus, and pertussis (DTaP) and Diphtheria and Tetanus (DT) which are mentioned in the compulsory immunization program for newborn babies worldwide. Monovalent vaccines are going to showcase steady market growth during the forecast period as growing incidence of clostridium tetani infection in the middle and low income countries primarily drives the monovalent vaccines market growth. It is given to adult population who have never received a tetanus vaccines during their childhood and thus monovalent vaccine is given to develop a strong immune response.

For more insights about the study, request a report sample

Hospitals are currently leading the end user segment for tetanus toxoid vaccines market. Compulsory immunization of tetanus toxoid vaccines in the children throughout the globe has resulted in significant increase in the number of inpatient visits to the primary healthcare centers worldwide. Proactive initiative adopted by Government healthcare agencies to provide free vaccines to government sponsored hospitals to encourage the immunization program further consolidate the market growth. Specialty clinics are expected to register rampant market growth in the near future owing to the increasing disposable income in middle income families, which frequently visit specialty clinics for immunization of children’s at affordable price.

Global tetanus toxoid vaccines market size and forecast were obtained by using “Bottom-up” and “Top-down” approaches. Extensive secondary research was conducted to understand the market insights and trends, followed by primary interviews to further validate the information sourced. The report provides both, qualitative and quantitative analyses of the market, the competitive landscape, and the preferred development strategies of key players which help to formulate competitive market strategies and make informed decisions.

The tetanus toxoid vaccines market research report presents the analysis of each segment from 2018 to 2027 considering 2020 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2027.

Historical & Forecast Period

• 2018-19 – Historical Year
• 2020 – Base Year
• 2021-2027 – Forecast Period

Market Segmentation:

By Type:

• Monovalent
• Polyvalent

By End-User:

• Hospitals
• Specialty Clinics
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Geographic Coverage:

North America currently holds a dominant position in the geography segment of the tetanus toxoid vaccines market. The market growth in the region is primarily driven by the mandatory immunization of children according to the vaccination guidelines provided by the USFDA. The presence of a well-established healthcare infrastructure and an affordable reimbursement scenario associated with immunization programs further contribute to the market growth in North America.

Europe is the second-largest regional segment for tetanus toxoid vaccines, largely due to the presence of major players such as Merck & Co. Inc., Sanofi Pasteur, GlaxoSmithKline, Plc., and others. These established players significantly influence the market growth in the region.

The Asia Pacific region is expected to be the fastest-growing regional segment for tetanus toxoid vaccines. The rising incidence of Clostridium tetani infection, which causes tetanus, is a key driver of market growth in the region. Additionally, the emergence of local players and the development of healthcare infrastructure further bolster the market growth in the Asia Pacific region.

Overall, the tetanus toxoid vaccines market is driven by the mandatory immunization of children in North America, the presence of major players in Europe, and the increasing incidence of Clostridium tetani infection in the Asia Pacific region. These factors contribute to the growth of the market in their respective regions.

Market Competition Assessment:

Key players operating in the global tetanus toxoid vaccines market are Sanofi Pasteur, Merck & Co. Inc., Pfizer, Inc., GlaxoSmithKline, Plc., and Bharat Biotec. Companies are exploring markets through expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Key Companies:

• Sanofi Pasteur
• GlaxoSmithkline, Plc.
• Merck & Co. Inc.
• Pfizer, Inc.
• Bharat Biotec
• Serum Institute Of India Limited
• Panacea Biotec Ltd.
• Astellas Pharma, Inc.
• Emergent Biosolutions, Inc.
• PT Bio Farma

Key Questions Answered by Tetanus Toxoid Vaccines Market Report:

• Global tetanus toxoid vaccines market forecasts from 2021-2027
• Regional tetanus toxoid vaccines market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country-level forecasts from 2021-2027 covering 15 major countries from the aforementioned regions
• Tetanus toxoid vaccines submarket forecasts from 2021-2027 covering the market by type, by end-user, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis pertaining to tetanus toxoid vaccines market
• Analysis of the key factors driving and restraining the growth of the global, regional and country-level tetanus toxoid vaccines markets from 2021-2027
• Competitive Landscape and market positioning of top 10 players operating in the tetanus toxoid vaccines market